id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-301800-ssdzd43t	Atal, Shubham	Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?	2020-10-13		.txt	text/plain	4509	187	44	Based on the results, the Indian drug regulatory agency recently approved itolizumab in July 2020 for 'restricted emergency use' for the treatment of CRS in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19. The Indian drug regulatory agency (Central Drug Standard Control Organisation, CDSCO) recently approved itolizumab for 'restricted emergency use' for treatment of cytokine release syndrome (CRS) in moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19, followed by a similar approval in Cuba [1, 2] . The drug was studied in an open-label, randomized, controlled, phase II trial at four hospitals in India to assess the safety and efficacy of itolizumab in preventing CRS in moderate to severe ARDS due to COVID-19 [7] . The approval of itolizumab for restricted emergency use to treat COVID-19 patients with the complication of moderate to severe ARDS comes at a time when cases and hospitalizations are increasing alarmingly; the mortality has exceeded 80 thousand in India [24] .	./cache/cord-301800-ssdzd43t.txt	./txt/cord-301800-ssdzd43t.txt